SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine

BPZE1 is a live attenuated vaccine currently in advanced clinical development for nasal immunization against pertussis. The ability of this vaccine to induce mucosal and systemic, humoral and cellular immunity make it an attractive mucosal delivery system for heterologous antigens to induce immunity especially in the respiratory tract. Here, we have developed a heterologous antigen expression system based on the pertactin-deficient BPZE1 derivative IB-V002 by using the SphB1 secretion system to present the SARS-CoV-2 nucleocapsid protein (N) as a model antigen to the respiratory mucosa. SphB1 is an autotransporter comprising a subtilisin-like passenger domain and a C-terminal ß-barrel domain. The passenger domain was replaced by the SARS-CoV-2 N protein. The recombinant gene was inserted into the urease locus of IB-V002 and placed under the control of the pertactin promoter and signal peptide. Immunoblot analyses indicated that the chimeric protein was produced and secreted by the recombinant strain named BT-V101. Mice intranasally immunized with BT-V101 induced N-specific IgG in serum and IFN-γ production by spleen cells. Importantly, a local N-specific CD8+ T cell response was observed in nose-associated lymphoid tissues by MHC class I tetramer staining. Additionally, immunization with BT-V101 efficiently primed mice to recombinant purified N protein given as a boost either intranasally or subcutaneously. These results demonstrate the suitability of the B. pertussis SphB1 secretion machinery to secret heterologous antigens for the development of a mucosal immunization vaccine platform with the induction of specific humoral and cellular, local, and systemic immune responses. • The SphB1 export system was used to secrete heterologous antigens by B. pertussis. • Recombinant B. pertussis induced systemic and local immunity to foreign antigens. • Recombinant B. pertussis efficiently primed immune responses to foreign antigens.

Authors

Institutions

Publication Details

Journal
Applied Microbiology and Biotechnology
Published
2026-05-29
DOI
https://doi.org/10.1007/s00253-026-13887-x
Primary Topic
Bacterial Infections and Vaccines
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine

Peter Goldstein, Violaine Dubois, Camille Locht, Lazara Elena Santiesteban-Lores et al.
Applied Microbiology and Biotechnology
Bacterial Infections and Vaccines
article

SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine

Peter Goldstein, Violaine Dubois, Camille Locht, Lazara Elena Santiesteban-Lores, Dominique Raze, Morgane Tardy, Anne‐Sophie Debrie, Loic Coutte
article en

Abstract

BPZE1 is a live attenuated vaccine currently in advanced clinical development for nasal immunization against pertussis. The ability of this vaccine to induce mucosal and systemic, humoral and cellular immunity make it an attractive mucosal delivery system for heterologous antigens to induce immunity especially in the respiratory tract. Here, we have developed a heterologous antigen expression system based on the pertactin-deficient BPZE1 derivative IB-V002 by using the SphB1 secretion system to present the SARS-CoV-2 nucleocapsid protein (N) as a model antigen to the respiratory mucosa. SphB1 is an autotransporter comprising a subtilisin-like passenger domain and a C-terminal ß-barrel domain. The passenger domain was replaced by the SARS-CoV-2 N protein. The recombinant gene was inserted into the urease locus of IB-V002 and placed under the control of the pertactin promoter and signal peptide. Immunoblot analyses indicated that the chimeric protein was produced and secreted by the recombinant strain named BT-V101. Mice intranasally immunized with BT-V101 induced N-specific IgG in serum and IFN-γ production by spleen cells. Importantly, a local N-specific CD8+ T cell response was observed in nose-associated lymphoid tissues by MHC class I tetramer staining. Additionally, immunization with BT-V101 efficiently primed mice to recombinant purified N protein given as a boost either intranasally or subcutaneously. These results demonstrate the suitability of the B. pertussis SphB1 secretion machinery to secret heterologous antigens for the development of a mucosal immunization vaccine platform with the induction of specific humoral and cellular, local, and systemic immune responses. • The SphB1 export system was used to secrete heterologous antigens by B. pertussis. • Recombinant B. pertussis induced systemic and local immunity to foreign antigens. • Recombinant B. pertussis efficiently primed immune responses to foreign antigens.

Applied Microbiology and Biotechnology
Centre National de la Recherche Scientifique (FR), Inserm (FR), Centre Hospitalier Universitaire de Lille (FR), Center for Infection and Immunity of Lille (FR), GlaxoSmithKline (Switzerland) (CH)
Good health and well-being
Openalex Percentile: Top 7%
Bacterial Infections and Vaccines
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.